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now the first line of treatment
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Background: Endovascular repair (EVR) is emerging as first-line treatment for patients with superior vena cava (SVC)
syndrome of benign etiology, but data on its durability remain scarce. The aims of this study were to assess the efficacy
and durability of EVR and compare results of EVR with open surgical reconstruction (OSR).
Methods: Data from 70 consecutive patients undergoing treatment for benign SVC syndrome between November 1983
and November 2006 were retrospectively reviewed.
Results: There were 30 males and 40 females (mean age, 41 years; range, 5-75 years). Etiology included indwelling
catheters or pacemaker wires in 35 patients, mediastinal fibrosis in 31, idiopathic thrombosis in 2, hypercoagulable
disorder in 1, and postsurgical thrombosis in 1. In 42 patients, OSR was done through a median sternotomy: repair was
with spiral saphenous vein in 22, expanded polytetrafluoroethylene (ePTFE) in 13, femoral vein grafts in 6, and human
allograft in 1. Fifteen OSRs followed failed EVR interventions. EVR was attempted in 32 patients and was successful in
28 (88%): 19 had stenting, 14 had percutaneous transluminal balloon angioplasty (PTA), 2 had thrombolytic therapy
with PTA, and 3 had stenting. All four technical failures subsequently underwent OSR. There were no early deaths in
either group. Periprocedural morbidity was 19% after OSR and 4% in the EVR group. Six early surgical graft failures were
successfully treated with surgical revision; one restenosis after EVR was restented. During a mean follow-up of 4.1 years
(range, 0.1-17.5 years) after OSR, 11 patients underwent 18 secondary interventions. Mean follow-up after EVR was 2.2
years (range, 0.2-6.4 years), and nine patients underwent 21 secondary EVR interventions. Primary, assisted primary,
and secondary patency rates of surgical bypass grafts were, respectively, 45%, 68%, and 75% at 3 and 5 years. Primary,
assisted primary and secondary patency rates after EVR were 44%, 96%, and 96% at 3 years. Assisted primary patency was
significantly higher in vein grafts than in ePTFE grafts (P  .05). Assisted primary and secondary patency was
significantly higher in patients undergoing stenting compared with PTA (P  .02). At last follow-up, 93% of patients in
both OSR and EVR groups had significant relief from symptoms.
Conclusions: OSR of benign SVC syndrome is effective, with durable long-term relief from symptoms. EVR is less invas-
ive but equally effective in the mid-term, albeit at the cost of multiple secondary interventions, and is an appropriate
primary treatment for benign SVC syndrome. OSR remains an excellent choice for patients who are not suitable for EVR
or in whom the EVR fails. ( J Vasc Surg 2008;47:372-80.)Benign etiologies historically have accounted for up to
22% of cases of superior vena cava (SVC) syndrome, with
half of these resulting from mediastinal fibrosis.1-3 A recent
report suggests that benign etiologies may now comprise
up to 40% of cases.4 This increase is primarily due to a rise
in the use of indwelling central venous catheters and cardiac
pacemakers during the past 2 decades, resulting in a higher
incidence of SVC thrombosis.
We have had a longstanding interest in this condition at
the Mayo Clinic. We have treated these patients with bypass
grafting from the innominate or jugular vein to the SVC or
right atrial appendage for 2 decades and have previously
reported our results after open surgical reconstruction (OSR)
and our preliminary results with endovascular repair (EVR). 5
During the last 5 years our practice has shifted signifi-
cantly towards EVR as primary therapy, and patients
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372treated by EVR have far outnumbered those undergoing
OSR (Fig 1). Several authors have reported initial success
with EVR; however, the durability of this approach remains
largely unknown, with few reports including long-term
follow-up.6-11 The aims of this study were to assess the
feasibility, efficacy, and durability of endovascular treat-
ment of benign SVC syndrome and to compare the results
of EVR with those after OSR.
METHODS
Patients. Clinical data of 70 consecutive patients with
SVC syndrome of benign etiology treated at the Mayo
Clinic from November 1983 to November 2006 were
retrospectively analyzed. Data were collected under a pro-
tocol approved by the Institutional Review Board in com-
pliance with Health Insurance Portability and Accountabil-
ity Act (HIPAA) standards. Data collected included
preoperative patient demographics, clinical status, nonin-
vasive and invasive imaging, operative and endovascular
procedural details, postprocedural imaging surveillance,
early and late adjunctive procedures, and clinical outcome
during follow-up. Patients with no clinical follow-up 1
year were categorized as “lost to follow-up.”
All patients underwent venography before intervention,
and the patterns of SVC stenosis/occlusion were classified
into four groups as described by Stanford and Doty.12 In the
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phy was the gold standard to define anatomy preoperatively
and confirm patency postoperatively. At present, computed
tomography (CT) venography is the first imaging study per-
formed and conventional venography is performed at the time
of attempted endovascular intervention. Patients were divided
into two groups according to the intervention performed at
our institution: 42 had open surgical reconstruction and 28
had endovascular repair (EVR).
Open surgical bypass. OSR was performed through a
median sternotomy.The choice of conduitwas determinedby
the surgeon. Autologous vein, either spiral saphenous or
femoral vein, was the conduit of choice if available. Externally
supported expanded polytetrafluoroethylene (ePTFE) was
used if a suitable autologous vein was unavailable. The tech-
nique of autologous spiral saphenous vein bypass grafting has
been described previously.5,13 The proximal anastomosis was
performed to the internal jugular or innominate vein, and the
distal anastomosis was to the SVC or right atrial appendage.
Endovascular intervention. EVR was performed
through percutaneous venous access of the common femoral
vein, through which 6F to 10F sheaths were placed and
hydrophilic guidewires and5F catheterswere used to cross the
stenotic/occlusive lesion. If the lesion could not be crossed
from this approach, the right internal jugular vein was ac-
cessed. Once wire access across the lesion was obtained, pri-
mary percutaneous transluminal balloon angioplasty (PTA)
using standard 10- to 16-mm angioplasty balloons was per-
formed, followed by stenting. If thrombolysis was determined
tobe appropriate beforePTAor stenting, a catheter of suitable
lengthwith side-holes was placed across the lesion and recom-
binant tissue plasminogen activator (r-TPA) was infused. Se-
rial imaging before PTA or stenting was obtained before
discontinuation of thrombolysis. Technical success was de-
fined as30% residual stenosis after intervention.
All surgical bypass grafts were imaged with venography
before the patient was discharged from the hospital. Post-
procedural anticoagulation was at the discretion of the
surgeon or interventionalist. Most patients were discharged
with warfarin therapy for oral anticoagulation and remained
on it for 3 months to indefinitely. All patients with a known
Fig 1. Treatment modalities in 70 consecutive patients with be-
nign superior vena cava syndrome over 23 years.thrombophilia risk factor, as well as OSR and EVR patientswith early (30 days) reconstruction failure, remained on
warfarin anticoagulation indefinitely, the remainder re-
mained on antiplatelet therapy with aspirin/clopidogrel.
During follow-up after OSR or EVR, patients under-
went surveillance imaging by duplex ultrasonography
(DUS), magnetic resonance imaging (MRI), CT, or
venography. In the early phase of the study, all surgical
patients were reviewed at 3 to 6 months and at 12 months
with a venogram at each visit. Patients were reviewed
annually thereafter, and grafts were imaged noninvasively
with CT orMRI, with venography being performed only in
patients with recurrent symptoms. With experience, it be-
came evident that stenoses requiring intervention were
associated with recurrence of symptoms, and in the later
stages of the study, most patients returned for follow-up
only if symptoms recurred. The EVR patients were fol-
lowed up with the latter protocol.
Post-treatment clinical outcome was graded according
to the Subcommittee on Reporting Standards in Venous
disease14: complete relief of symptoms, 3; moderate clin-
ical improvement,2; mild clinical improvement,1; and
no clinical change, 0.
Statistical analysis. Kaplan-Meier survival curves
were used to estimate bypass graft and endovascular pa-
tency with respect to primary patency, assisted primary
patency, and secondary patency. The date of the initial
bypass graft or endovascular procedure was the starting
point, and the dates where an endovascular or surgical
intervention was performed to maintain assisted primary or
secondary patency were counted as events. The 95% confi-
dence intervals (CI) are reported for 1, 3, and 5 years. Risk
factors were assessed univariately for bypass graft or endo-
vascular patency using a log-rank test. A value of P  .05
was considered statistically significant. Data analysis was
performed using SAS 9 software (SAS Institute, Cary, NC).
RESULTS
Patients. The study included 30 males and 40 females
(mean age, 41 years; range, 5-75 years) who were treated for
SVC syndrome of benign etiology. Of these, 42 patients (18
male, 24 female; mean age, 40 years; range, 5-69 years)
underwent OSR and 28 (12 male, 16 female; mean age, 47
years; range, 11-75 years) underwent EVR. All patients had
significant morbidity from SVC syndrome despite maximal
medical measures. The most common symptoms were head
and neck fullness and dyspnea on exertion, and the most
common signs were head and neck swelling and distended
collateral veins.Mean duration of symptoms before treatment
was 21.4months (range, 1-72months) in theOSRgroup and
11.9 months (range, 0.25-96 months) in the EVR group.
The predominant etiology of SVC syndromewasmedias-
tinal fibrosis in theOSRpatients (n22, 52%) and indwelling
catheter or pacemaker wire related thrombosis in the EVR
group (n  19, 68%). In one OSR patient, antithrombin III
deficiency was the sole cause of SVC syndrome (Table I).
Additional thrombophilic risk factors in the OSR patients
included a history of deep venous thrombosis (DVT) in 8
(25%), protein C/S deficiency in 2 (4%), and one patient (2%)
ntion.
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pholipid antibody, and Behçet disease. Additional risk factors
amongst the EVR group included previous history of DVT in
two (7%), history of neck irradiation in one (3%), and Behçet
disease in one (3%).
In the OSR group, 17 patients had undergone prior
attempts at repair elsewhere. Two patients had undergone
OSR through a sternotomy. Of attempted EVR in 15
patients, 10 were initially successful but eventually failed.
Failed EVR included thrombolysis in 1, thrombolysis with
PTA or stent in 3, PTA or stent in 6, and failed attempt at
recanalization in 5. Of these, 14 were occluded and one had
a 70% stenosis at the time of presentation to our institu-
tion. We attempted a further endovascular recanalization
Table I. Primary causes of benign superior vena cava synd
Causes
Total (n70),
No. (%)
Mediastinal fibrosis 31 (44)
Sclerosing mediastinal fibrosis 16 (23)
Histoplasmosis 12 (17)
Mediastinal granulomatous disease 2 (3)
Postradiation 1 (1)
Venous thrombosis 38 (54)
Indwelling catheter/pacemaker wire 33 (47)
Ventriculoatrial shunt 2 (3)
Hypercoagulable state 1 (1)
Idiopathic 2 (3)
Surgical excision 1 (1)
*Fisher’s exact test, two-tail P comparing surgical and endovascular interve
Table II. Classification* and underlying etiology of 70 pa
stenosis/occlusion
Type Definition
Total (n  70),
No. (%)
S
I 90% stenosis of the SVC
with patency and
antegrade flow of the
azygos–right atrial
pathway
6 (9) 3 (7) (
II 90% stenosis or
occlusion of the SVC
with patency and
antegrade flow in the
azygos–right atrial
pathway
16 (23) 4 (10)
3; id
III 90% stenosis or
occlusion of the SVC
with reversal of azygos
blood flow
28 (40) 15 (36
7; ve
IV Occlusion of the SVC and
one or more of the
major caval tributaries
including the azygos
systems
20 (28) 20 (47
9; ve
hype
prio
idio
SVC, Superior vena cava.
*Stanford and Doty.12
†Fisher exact test, two-tail P.for four of these occlusive lesions, but these were unsuc-cessful, and they eventually underwent OSR. No patient
successfully treated in the EVR group had undergone a
previous attempt at repair.
Preoperative imaging evaluation. All patients under-
went preprocedural venography, and the SVC lesion was
classified according to the extent of stenosis/occlusion.
Additional imaging included CT (86%), DUS (68%), and
MRI (11%). OSR patients had 15 type III lesions (36%) and
20 type IV (47%), whereas 12 EVR patients (43%) had type
II lesions and 13 had type III (46%; Table II). No patient in
the EVR group had a type IV SVC occlusion (P  .001).
Open surgical reconstruction. Forty-two bypass
grafts were performed in 42 patients. Spiral saphenous vein
graft (SSVG) was used in 22 patients (52%), ePTFE in 13
e in 70 patients
Surgical (n42),
No. (%)
Endovascular (n  28),
No. (%) P*
22 (52) 9 (32) .14
13 (31) 3 (11) .08
6 (14) 6 (21) .52
2 (5) 0 (0) .51
1 (2) 0 (0) .99
19 (45) 19 (68) .09
14 (33) 19 (68) .007
2 (5) 0 (0) .51
1 (2) 0 (0) .99
2 (5) 0 (0) .51
1 (2) 0 (0) .99
s based on venographic pattern of superior vena cava
al (n  42),
o. (%)
Endovascular (n  28),
No. (%) P†
astinal fibrosis, 3) 3 (11) (mediastinal fibrosis, 1;
venous thrombosis, 2)
.67
iastinal fibrosis,
hic, 1)
12 (43) (mediastinal fibrosis,
3; venous thrombosis, 9)
.003
diastinal fibrosis,
thrombosis, 8)
13 (46) (mediastinal fibrosis,
5; venous thrombosis, 8)
.46
diastinal fibrosis,
thrombosis, 8;
ulable state, 1;
ery, 1;
, 1)
0 (0)  .0001romtient
urgic
N
medi
(med
iopat
) (me
nous
) (me
nous
rcoag
r surg
pathic(31%), and femoral vein in 6 (14%). Cadaveric iliocaval vein
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topic liver transplantation for sclerosing cholangitis (Table
III). There were 40 straight grafts and two bifurcated SSVGs.
In one instance, the contralateral left innominate vein was
implanted into the straight vein graft. Two pediatric patients,
age 5 and 8, underwent OSR with a SSVG and PTFE graft,
respectively. The etiology in these two patients was a prior
SVC resection and antithrombin III deficiency.
The mean pressure gradient across the SVC occlusion
recorded in 24 patients was 21 mm Hg (range, 9-43 mm
Hg) before reconstruction and 6 mmHg (range, 0-13 mm
Hg) after the reconstruction. All bypass grafts were imaged
before discharge, and 35 of 42 patients (83%) were pre-
scribed oral anticoagulation therapy at discharge. The me-
dian length of stay was 9 days (range, 4-48 days).
Endovascular repair. Primary EVR was performed in
28 patients and attempted in an additional four. Technical
success was achieved 28 of 32 patients (88%). Four patients
underwent primary PTA (14%), and 19 patients (68%)
underwent stenting after PTA. Details of type and location
of intervention are in Table III. One pediatric patient (age
11) underwent stenting for catheter-related thrombosis.
Five patients presented with subacute SVC syndrome (du-
Table III. Procedural details of 42 patients with open
surgical reconstruction and 28 patients with endovascular
repair
Type of repair Patients, No. (%)
Open surgical reconstruction
Autologous vein 28 67
Spiral saphenous vein 22 52
Straight grafts (19) (43)
Bifurcated grafts (2) (5)
Straight graft  reimplantation
opposite innominate vein (1) (2)
Femoral vein 6 14
Iliocaval allograft 1 2
Expanded polytetrafluoroethylene 13 31
Total 42 100
Endovascular repair
Catheter-directed thrombolysis with PTA 2 7
Catheter-directed thrombolysis with
stenting 3 11
PTA 4 14
Stenting 19 68
Total 28 100
Location of PTA or stenting
SVC 19 68
SVC and innominate vein 5 18
Innominate vein 3 11
SVC and internal jugular vein 1 3
Type of stent
Wallstent (Boston Scientific, Natick,
Mass) 6 21
S.M.A.R.T (Cordis, Piscataway, NJ) 6 21
Palmaz (Cordis, Piscataway, NJ) 5 18
Viabahn (W.L. Gore, Newark, Del) 3 11
Lumminexx (C.R. Bard, Covington, Ga) 1 3
Protégé (eV3 Inc, Plymouth, Minn) 1 3
PTA, Percutaneous transluminal angioplasty; SVC, superior vena cava.ration of symptoms, 1-4 weeks) and were initially treatedwith catheter-directed thrombolysis, followed by PTA (n
2) or stenting (n  3). The duration of thrombolytic
therapy did not exceed 48 hours.
The mean pressure gradient across the SVC stenosis or
occlusion recorded in 11 patients was 12 mm Hg (range,
5-22 mm Hg) preintervention and 2 mm Hg (range, 0-6
mmHg) postintervention. Warfarin therapy was prescribed
to 22 patients (78%) at discharge, and therapy for the rest
was aspirin or clopidogrel. The median length of stay was 2
days (range, 1-14 days).
Early results (within 30 days)
Morbidity and mortality. There were no in-hospital
or early postoperative deaths. Eight patients (19%) who
underwent OSR had 11complications. In one patient in the
EVR group (4%), an arm hematoma developed at a periph-
eral intravenous access site while receiving thrombolysis,
which was treated non-surgically (Table IV).
Patency of reconstruction for open surgical repair. In
six patients (14%) in the OSR group, early graft throm-
bosis developed within the first 2 postoperative days, all
of which were successfully treated with surgical revision.
Three occluded ePTFE grafts underwent surgical throm-
bectomy. One ePTFE graft occluded on the first postop-
erative day owing to inflow compromise and was re-
placed with a new ePTFE graft with inflow from the
contralateral internal jugular vein. Two SSV bifurcated
grafts had occlusion of the side limb and were thrombec-
tomized and revised; however, one side limb rethrom-
bosed early. All bypass grafts, except one limb of a
bifurcated graft, were patent at the time of discharge.
None of these six patients sustained a complication due
to the early repeat surgical intervention to maintain
secondary patency, and their length of stay was not
significantly prolonged (median, 10 days; range, 9-22
days). The 30-day primary, assisted primary, and second-
ary patencies were 93%, 98%, and 100%, respectively.
Patency of reconstruction for endovascular re-
pair. In the EVR group, one patient (4%) required early
reintervention for a nonocclusive residual thrombus proxi-
Table IV. Thirty-day complication rate after open
surgical reconstruction or endovascular repair for superior
vena cava syndrome
Complication Patients, No.
Surgical 8
Mediastinal hematoma requiring evacuation 1
Deep venous thrombosis 2
Pulmonary embolus 1
Prolonged mechanical ventilation 2
Pericardial effusion requiring drainage 1
Tracheostomy, prolonged mechanical
ventilation, pleural effusion requiring
drainage, pneumonia 1
Endovascular 1
Arm hematoma 1mal to an innominate vein stent on postoperative day 1.
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new stent. In another patient with thrombosis related to a
pacemaker lead, rethrombosis of the SVC developed 18
days after catheter-directed thrombolysis and stenting. No
further intervention was performed in this patient. The
30-day primary, assisted primary, and secondary patencies
were 93%, 96%, and 96%, respectively.
Late results
Mortality. Mean follow-up in the entire patient co-
hort was 3.2 years (range, 0.1-17 years). In the OSR group,
14 patients were lost to follow-up and five late deaths
occurred during a mean follow-up of 4.1 years (range,
0.1-17.5 years). The first patient, with longstanding Crohn
disease, died of new bronchogenic carcinoma after remain-
ing asymptomatic for 8 years after SSVG. One patient died
of septic complications of longstanding tuberculous perito-
nitis 17 months after an ePTFE graft for central catheter–
related thrombosis. Three patients died of unknown causes
at 8 months, and 3 and 8 years after OSR.
The mean follow-up in the EVR group was 2.2 years
(range, 0.2-6.4 years). Seven patients were lost to follow-
up. Cardiac failure resulted in one late death at 4.5 years.
This patient was awaiting heart transplantation after under-
going thrombolysis and stent placement for SVC syndrome
from central vein thrombosis due to a pacemaker wire lead.
Patency. In the OSR group, postoperative graft sur-
veillance was performed with venography at 3, 6, and 12
months and DUS, MRI, or CT scan yearly thereafter, or
earlier if symptoms recurred. Mean duration of follow-up
determined from the date of the last imaging study was 3.4
years (range, 1 day-17.4 years). To maintain patency dur-
ing follow-up, 11 patients required 18 reinterventions
(PTA, 10; stenting, 7, thrombolysis, 1); and seven of these
were within the first year (Fig 2).
Seven grafts eventually occluded during follow-up, of
which three underwent an intervention. One SSVG graft
Fig 2. Secondary interventions required to maintain patency in
(A) the open surgical group (n  42) and (B) the endovascular
group (n  28). The bars represent the percentage of patients in
each group, and the line graphs represent the total number of
interventions. Secondary interventions in the surgical group in-
clude new superior vena cava bypass grafts in two patients after
occlusion of the primary grafts.was successfully treated with recanalization and stenting,one occluded ePTFE graft was replaced with a new SSVG,
and one occluded SSVG was replaced with a femoral vein
graft. The remaining four occluded grafts did not undergo
intervention; two of these were re-do grafts in patients with
prior OSR bypasses. No complications or deaths were
elated to the secondary EVR or OSR interventions.
The 1, 3, and 5-year cumulative primary patency rates
of OSR were 58% (95% CI, 43%-77%), 45% (95% CI,
30%-68%), and 45% (95% CI, 29%-68%); assisted primary
patency rates were 81% (95% CI, 69%-95%), 68% (95% CI,
52%-88%), and 68% (95% CI, 49%-88%); and secondary
patency rates were 85% (95% CI, 74%-98%), 75% (95% CI,
61%-94%), and 75% (95% CI, 57%-94%; Fig 3, A). After
excluding PTFE grafts and analyzing only the 28 vein grafts
and the cadaveric allograft, the 5-year rates were cumulative
primary patency, 49% (95% CI, 31%-75%); assisted primary
patency, 78% (95% CI, 59%-98%); and the secondary pa-
tency, 81% (95% CI, 63%-100%).
In the EVR group, the mean length of follow-up based
on the last imaging was 1.8 years (range, 0 days-6.3 years).
Nine patients required 21 secondary interventions to main-
tain patency, four of which were within the first year (Fig
2). These included 19 PTAs, one stent, and one thrombol-
ysis, followed by stenting. Secondary interventions were
Fig 3. A, Cumulative primary, assisted primary, and secondary
patency rates at 1, 3, and 5 years of open surgical reconstruction (n
 42). Range bars represent the standard error of the mean10%.
B, Cumulative primary, assisted primary, and secondary patency
rates at 1 and 3 years of endovascular repair (n  28). Range bars
represent the standard error of the mean 10%.performed in 55% (5 of 9) of patients with mediastinal
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catheter/pacemaker wire-related thrombosis; this trend
did not reach statistical significance (P  .2). One patient
with mediastinal fibrosis underwent 10 additional PTAs
during a 6.5-year period to treat symptomatic in-stent
restenoses. These episodes of restenosis were immediately
treated with PTA, and his symptoms would promptly re-
solve. The restenotic lesion was amenable to an endovascu-
lar intervention each time, and the patient had a strong
preference for this treatment modality vs surgical repair.
His stent was still patent at the last follow-up. One patient
chose to undergo SSVG at another institution after the
third restenosis after EVR. One patient was found to have
asymptomatic stent occlusion on follow-up imaging, and
no further intervention was performed.
There were two complications (cardiac tamponade)
and no deaths related to secondary endovascular interven-
tions. The episodes of cardiac tamponade occurred at the
time of second and sixth PTA, were confirmed with echo-
cardiography, and were successfully managed with imme-
diate pericardiocentesis, with no further sequelae.
The cumulative 1- and 3-year rates of EVR were pri-
mary patency, 70% (95% CI, 51%-94%) and 44% (95% CI,
22%-82%); assisted primary patency, 96% (95% CI, 87%-
100%) and 96% (95% CI, 82%-100%); and secondary pa-
tency, 96% (95% CI, 87%-100%) and 96% (95% CI, 82%-
100%). One additional EVR failed at 3.9 years, but the
life-table analysis was only reported out to 3 years because
of diminishing numbers beyond this point adversely affect-
ing accuracy (Fig 3, B).
No significant difference was found in primary patency
(P .91), assisted primary patency (P .29), or secondary
patency (P  .36) when OSR was compared with EVR.
Outcome. At the last clinical assessment, 39 of 42 pa-
tients (93%) in the OSR group had mild or no symptoms
compared with 26 of 28 patients (93%) in the EVR group (P
 .99; Fig 4). Only one OSR patient and two EVR patients in
the combined cohort had no clinical improvement after treat-
ment. Graft or endovascular occlusion developed in six pa-
tients (4 OSR, 2 EVR) for which no further intervention was
performed. One EVR patient remained symptomatic after
early stent rethrombosis; the remaining 5 patients maintained
Fig 4. Grading of symptom relief at last clinical follow-up in
patients undergoing open surgical reconstruction (n  42) or
endovascular repair (n  28).some clinical improvement despite reocclusion.Risk factor analysis. Univariate analysis was per-
formed to assess the impact of sex, age (40 years vs 40
years), type of SVC occlusion (type I/II vs type III/IV),
etiology (mediastinal fibrosis vs venous thrombosis), his-
tory of an EVR (PTA or stenting), type of bypass conduit
(autologous vs PTFE), and type of intervention (PTA vs
stenting) on patency (Table V). At 3 years, the ePTFE
grafts demonstrated worse assisted primary patency than
autologous grafts (P  .05), with rates of 26% (95% CI,
5%-100%) vs 78% (95% CI, 62%-98%), respectively. At 3
years, stenting compared with PTA had improved assisted
primary and secondary patency (P  .02), with rates of
100% vs 88% (95% CI, 57-100), respectively.
DISCUSSION
Although SVC syndrome of benign etiology remains an
uncommon disease, increasing use of indwelling central cath-
eters and pacemaker wires in the past 20 years has led to a
marked increase in its incidence. More than 5 million central
venous catheters and 170,000 pacemakers are now implanted
annually in the United States and are associated with upper
extremity or central vein DVT in 7% to 33% of patients.15-18
SVC syndrome reportedly occurs in 1% to 3% of patients with
central venous catheters and in 0.2% to 3.3% of patients with
implanted pacemakers.4,19 Catheter-related thrombosis has
overtaken mediastinal fibrosis as the leading cause of this
syndrome. In the past, mediastinal fibrosis comprised up to
80% of cases of benign SVC syndrome,1-3 but recent data
attribute up to 74% of new cases to indwelling catheters or
wires.4,6 In our present series, 57% of cases were SVC throm-
boses related to catheters or wires.
Until recently,OSRhas been themainstay of treatment of
these patients in contrast to SVC syndrome secondary to
malignancy, where EVR has long been the accepted mode of
treatment. Patients with benign SVC syndrome are younger,
with a longer life expectancy, and therefore need a good,
durable reconstruction. OSR for benign SVC syndrome has
been performed with low morbidity and mortality and excel-
lent long-term results. Doty et al20 reported no perioperative
deaths and 87.5% graft patency at 10.9 years associated with
complete resolution of symptoms in 93% of patients after 16
SSVGs. Similar results have been reported from our institu-
tion, with no operative mortality, 80% graft patency at 5 years
(90% in vein grafts), and 79% symptom relief.5
EVR is rapidly becoming the preferred primary method
of treatment of benign SVC syndrome, along with the
widespread increase in EVR for all vascular problems. Com-
mensurate with this global change, our practice has also
shifted significantly towards EVR as primary therapy, with
most patients undergoing an attempt at EVR. In eight of
13 patients operated on in the last 5 years, an endovascular
intervention had failed or was unsuccessful.
Our patency rates ofEVRare comparablewithother small
series that demonstrate 57% to 79% primary patency and 85%
to 100% primary-assisted primary or secondary patency.6-8
Graft patency was maintained during longer follow-up in the
OSR group, with most secondary interventions being per-
formedwithin the first few years after the operative procedure.
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tions continued over the mid-term, although the small num-
bers of patients make it difficult to predict a difference (Fig 2).
Symptom relief was excellent and comparable in both groups
during the study period (Fig 4).
The major advantage of endovascular therapy over
open reconstruction is decreased procedure-related mor-
bidity and shorter recovery period in these young patients
in the prime of their working lives. OSR, however, was
associated with excellent long-term outcome without the
continuing need for reinterventions over time. Although
EVR was associated with very little initial morbidity, two
patients presented with cardiac tamponade from intraperi-
cardial rupture during repeat EVR in the follow-up period.
Of interest, both cases of pericardial tamponade occurred in
patients who underwent subsequent repeat PTA for reste-
nosis (second and sixth reinterventions, respectively). Peri-
cardial tamponade after EVR for both benign and malig-
nant SVC syndrome is uncommon, and whether it is
attributable to stenting or PTA is unknown.21 Both cases of
pericardial tamponade were immediately recognized, con-
firmed with echocardiography, and promptly treated with
ultrasound-guided pericardiocentesis.
Overall, EVR has become the primary mode of treat-
Table V. Univariate analysis* of clinical and procedural ri
reconstruction or endovascular repair
Risk factor
Surgical patency
Patients, No
Primary
% P
Sex
Female 24 51 .70
Male 18 40
Age
40 23 28 .06
40 19 68
SVC obstruction type
Type I/II 7 57 .15
Type III/IV 35 40
Etiology
Mediastinal fibrosis 22 43 .83
Central line/wire 16 50
Prior endovascular
intervention
Yes 10 54§ .75
No 27 49
Type of bypass graft
PTFE 13 23 .58
Vein† 28 49
Endovascular intervention‡
PTA . . . . . . . . .
Stenting . . . . . .
SVC, superior vena cava; PTFE, polytetrafluoroethylene; PTA, percutaneou
*Log-rank test.
†Includes 28 vein grafts and 1 iliocaval allograft.
‡Includes 23 primary endovascular interventions and excludes 5 patients wh
§Kaplan-Meier estimates of patency at only 1 year.
Kaplan-Meier estimates of patency at only 2 years.ment of SVC syndrome of benign etiology for the afore-mentioned reasons, despite the greater need for reinterven-
tion possibly extending out to the long-term. Although not
statistically significant, a trend was noted toward more
reinterventions after EVR in patients with mediastinal fi-
brosis (55%) than in those with catheter-related thrombosis
(26%). Further follow-up is needed to clarify this fact, and
this may ultimately guide the choice of initial treatment.
Whether thrombolysis before PTA/stenting in the acute-
on-chronic occlusions related to indwelling catheters affects
long-term patency is not clear. In a small series by Gray et al, 22
initiation of thrombolysis5 days of onset of symptoms was
associated with relief of symptoms. Other studies have de-
scribed the use of thrombolysis before stenting for benign
SVCsyndrome, but outcomes in this subsetwere not reported
separately.6,10 Five patients in our study with acute-on-
chronic catheter-related SVC occlusion with symptoms rang-
ing from1 to 4weeks underwent catheter-directed thrombol-
ysis before PTA or stenting. All five were technically
successful, but rethrombosis of the EVR occurred in two
patients, one at 18 days and the other at 3.6 years. Our
practice for patients with catheter-related thrombosis is to
proceed initially with thrombolysis if the duration of symp-
toms is 4 weeks. If the venous thrombosis is due to an
indwelling central catheter, the catheter should be removed if
tors on patency in patients undergoing open surgical
Endovascular patency
condary
Patients, No.
Primary Secondary
P % P % P
.30 16 57 .78 92 0.69
12 27 100
.78 10 56§ .03 100 0.17
18 78 94
.16 15 45 .88 92 0.27
13 32 100
.84 9 29 .90 100 0.17
19 63 94
.94 . . . . . . . . . . . . . . .
. . . . . . . . .
.35 . . . . . . . . . . . . . . .
. . . . . . . . .
. . . 4 42 0.31 88 0.02
19 40 100
sluminal angioplasty.
erwent thrombolysis.sk fac
Se
%
70
83
74
78
100
69
74
81
86
75
42
81
. . .
. . .
s tran
o undfeasible and replaced after successful PTA or stenting. Throm-
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Volume 47, Number 2 Rizvi et al 379bosis related to a pacemaker leadmay require a laser-sheath to
temporarily extract the lead and replace it after completion of
thrombolysis and PTA or stenting.23
As with endovascular interventions in general, the shorter
the length of the occlusion the more amenable it is to a
successful EVR. No patient in our series with a type IV SVC
occlusion was treated by endovascular means. We attempted
primary EVR in two patients with type IV lesions but were
unsuccessful. This would suggest that this subgroup of pa-
tientsmight beunsuitable anatomically for anEVR.However,
Qanadli et al11 reported successful stenting in six patients with
type IV SVC occlusions from benign causes, with rapid reso-
lution of symptoms. Bornak et al10 reported similar success in
two patients, but neither commented on maintenance of
patency in this subgroup of patients.
Although we were unsuccessful in treating a type IV
occlusion in our study patients, making this subgroup
possibly unsuitable for EVR, we believe it is not unreason-
able to attempt recanalization of this type of occlusion. Of
15 patients undergoing OSR after failed EVR, the SVC
occlusions were type IV in eight (53%) and type III in six
(40%). The question arises whether all these were long
occlusions at the outset or became so after EVR, with
likelihood of repeat interventions and further extension of
stents, and does this adversely affect the outcome of even-
tual OSR? Although this certainly remains a consideration,
we were not able to make a definite determination because
the original venous imaging and intervention was per-
formed elsewhere in all patients. We have not yet had to
performOSR on any patients successfully treated with EVR
at our institution, although one patient chose to have an
SVC bypass at another institution for restenosis of a type II
lesion. In our current experience, long-term graft patency
was not adversely affected in these patients undergoing
long bypasses after occlusion of their EVRs.
Despite the shift towards primary EVR for patients with
benign SVC syndrome, OSR remains an excellent option in
selected patients. Spiral saphenous vein is our preferred
conduit; however, femoral vein provides comparable pa-
tency when saphenous vein is unavailable, albeit at the risk
of developing sequelae of lower extremity venous hyperten-
sion.24 After occlusion of side branches occurred in two
patients early in our experience, we have shied away from
bilateral reconstructions and have found that collateraliza-
tion across the midline is usually adequate to decompress
both sides with a single graft. Since analysis and report of
our experience 5 years ago, which revealed poorer patency
with ePTFE compared with vein grafts, we have avoided
long reconstructions with ePTFE.5 Data from treatment of
malignant SVC syndrome suggest that short, predomi-
nately intrathoracic ePTFE grafts have improved patency vs
longer ePTFE grafts originating from the internal jugular
vein.25,26 Since our last report, we have performed five
short ePTFE bypass grafts originating from the innominate
vein, and only one has required subsequent stenting for an
anastomotic stenosis to maintain assisted primary patency.
Our practice paradigm has shifted dramatically in the
past 7 years. Our present philosophy for the managementof patients who present with benign SVC syndrome unre-
sponsive to medical therapy, regardless of etiology, is to
initially attempt an EVR if possible. Patients with acute or
subacute venous thrombosis may benefit from catheter-
directed thrombolysis before PTA or stenting. Only pa-
tients who have a failed EVR or whose occlusion cannot be
recanalized are considered for OSR.
CONCLUSION
Endovascular treatment is an appropriate primary inter-
vention in patients with superior vena cava syndrome of
benign etiology. It is less invasive with lower morbidity
compared with open surgical reconstruction with equal
efficacy and patency in the mid-term, albeit at the cost of
multiple secondary interventions. It does not adversely
affect the feasibility or patency of subsequent open surgical
reconstruction. Surgical bypass is associated with durable
long-term relief from symptoms of superior vena cava syn-
drome and remains an excellent option in patients not
suitable for or who fail endovascular treatment
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